Focus: Compass Pathways is a UK-based biotechnology company specializing in psilocybin-assisted therapy for psychiatric disorders, positioned at the forefront of the psychedelic medicine renaissance. The company is advancing a pipeline focused on treatment-resistant depression, major depressive disorder, anorexia nervosa, and PTSD.
Profile data last refreshed 2h ago · AI intelligence enriched 1mo ago
Contracting — net -48 jobs in 30d
17 added, 65 removed. Active reduction in progress.
Best fit for commercial-track professionals betting on psychedelic psychiatry becoming mainstream; riskier for R&D scientists or those seeking mature support functions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Compass Pathways
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Compass Pathways's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Compass Pathways drug company moves U.S. headquarters to Jersey City - NJ.com
Compass Pathways drug company moves U.S. headquarters to Jersey City NJ.com
Synthetic Shrooms Corp Compass Pathways Opens US Office in Jersey City - Heady NJ
Synthetic Shrooms Corp Compass Pathways Opens US Office in Jersey City Heady NJ
How J&J paved the way for Compass’ coming psychedelic drug launch - BioPharma Dive
How J&J paved the way for Compass’ coming psychedelic drug launch BioPharma Dive
As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety - Fierce Biotech
As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety Fierce Biotech
COMPASS Pathways (NasdaqGS:CMPS) Stock Forecast & Analyst Predictions - Simply Wall Street
COMPASS Pathways (NasdaqGS:CMPS) Stock Forecast & Analyst Predictions Simply Wall Street
Analysts Are Bullish on These Healthcare Stocks: COMPASS Pathways (CMPS), Ocugen (OCGN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: COMPASS Pathways (CMPS), Ocugen (OCGN) The Globe and Mail
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo